Feed NGNE
NG

Neurogene Inc.

NGNE · NASDAQ

$32.09 -3.26% (-$1.08)
1M -19.05%
Market Cap $512.2M
P/E Ratio -
Div. Yield -
ROE 45.11%

Bulios Fair Price

$28.7

10.6% downside

Trenutna cena

$32.09

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price je delnica NGNE trenutno precenjena glede na svojo tržno ceno. Kako deluje?

Odkleni pošteno ceno

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Piotroski F-Score Weak
1/9
Valuation
79 /100
Cheap
P/B 2.36x
P/E N/A
EV/EBITDA N/A
Growth
100 /100
Growing
Book val. growth 39.00%
EPS growth N/A
Rev. growth N/A
Profitability
-
N/A
Gross margin N/A
Net margin N/A
Op. margin N/A
Quality
0 /100
Poor
ROIC 53.72%
ROE 45.11%
ROA 45.47%
Debt
69 /100
Low
Debt/Equity 0.04x
Current ratio 10.64x
Int. coverage -55,554.00x
Stability
21 /100
Unstable
Beta 1.96x
EPS volatility 43.06%
Profitable years 0

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o NGNE
Online

O podjetju

Neurogene Inc. is an American biopharmaceutical company focused on the development of innovative therapies for the treatment of genetic neurological disorders. The company specializes in researching and developing gene therapy-based drugs that have the potential to treat and improve the lives of patients with genetically inherited neurological disorders.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Biotechnology

CEO

Rachel L. McMinn

Employees

131

Headquarters

New York City

Prihajajoči dogodki

12 NOV.

Earnings

Upcoming earnings report

52d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.